title: Evaluation of the anti-inflammatory activity of riparin II (O-methil-N-2-hidroxi-benzoyl tyramine) in animal models.
abstract: Riparin II (RipII), an alkamide isolated from the green fruit of Aniba riparia, was tested in the various animal models of inflammation to investigate its anti-inflammatory activity. Male Wistar rats (180-240g) were treated with RipII by gavage at doses 25 or 50mg/kg, before initiating the inflammatory responses. The tests used were paw edema induced by carrageenan, dextran, histamine or serotonin; peritonitis induced by carrageenan and fMLP, as well as the measurement of MPO activity, TNF-α and Il-1β amount in the peritoneal fluid. In the animal models of carrageenan and dextran-induced paw edema, the animals treated with RipII showed lower edema than those of the control group. Treatment with RipII also reduced the paw edema induced by histamine but not serotonin. In the carrageenan-induced peritonitis model, treatment with RipII reduced leukocyte migration, the MPO activity and the amount of TNF-α and IL-1β in the peritoneal fluid. In summary, these results indicate that RipII has an anti-inflammatory activity in chemical models of acute inflammation. RipII might be directly or indirectly inhibiting the activity, production or release of pro-inflammatory mediators involved in the generation of the pain associated with inflammation.
authors.affiliation: Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil. clea@ufc.br
authors.forename: Alyne Mara Rodrigues
authors.initials: AM
authors.lastname: de Carvalho
authors.forename: Nayrton Flávio Moura
authors.initials: NF
authors.lastname: Rocha
authors.forename: Leonardo Freire
authors.initials: LF
authors.lastname: Vasconcelos
authors.forename: Emiliano Ricardo Vasconcelos
authors.initials: ER
authors.lastname: Rios
authors.forename: Marília Leite
authors.initials: ML
authors.lastname: Dias
authors.forename: Maria Izabel Gomes
authors.initials: MI
authors.lastname: Silva
authors.forename: Marta Maria
authors.initials: MM
authors.lastname: de França Fonteles
authors.forename: José Maria Barbosa
authors.initials: JM
authors.lastname: Filho
authors.forename: Stanley Juan Chavez
authors.initials: SJ
authors.lastname: Gutierrez
authors.forename: Francisca Cléa Florenço
authors.initials: FC
authors.lastname: de Sousa
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D004195:Disease Models, Animal; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D010538:Peritonitis / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014439:Tyramine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D001549:Benzamides; C521850:N-(2-hydroxybenzoyl)tyramine; D017392:Thiobarbituric Acid Reactive Substances; D008315:Malondialdehyde; D014439:Tyramine
keywords: Alkamides; IL1-β; Inflammation; MPO; N-formyl-methionyl-leucyl-phenylalanine; Pain; Riparin II; TNF-α; fMLP; interleukin; myeloperoxidase; tumor necrosis factor